Short Interest in Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Rises By 79.2%

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 8,600 shares, a growth of 79.2% from the February 28th total of 4,800 shares. Based on an average daily trading volume, of 497,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.1% of the shares of the company are short sold.

Sol-Gel Technologies Price Performance

SLGL traded up $0.02 during trading on Friday, hitting $0.55. 45,028 shares of the stock traded hands, compared to its average volume of 252,800. Sol-Gel Technologies has a twelve month low of $0.33 and a twelve month high of $1.65. The business has a 50 day moving average price of $0.65 and a 200 day moving average price of $0.69. The company has a market cap of $15.32 million, a price-to-earnings ratio of -1.62 and a beta of 1.29.

Hedge Funds Weigh In On Sol-Gel Technologies

A hedge fund recently bought a new stake in Sol-Gel Technologies stock. Raymond James Financial Inc. purchased a new position in shares of Sol-Gel Technologies Ltd. (NASDAQ:SLGL) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 108,990 shares of the company’s stock, valued at approximately $101,000. Raymond James Financial Inc. owned 0.39% of Sol-Gel Technologies as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 26.18% of the company’s stock.

Sol-Gel Technologies Company Profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc, develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.